title: Predictors of long-term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial.
authors.affiliation: Hospital la Paz, IdiPAZ, Madrid, Spain.
authors.forename: Jose
authors.initials: J
authors.lastname: Arribas
authors.forename: Federico
authors.initials: F
authors.lastname: Pulido
authors.forename: Andrew
authors.initials: A
authors.lastname: Hill
authors.forename: Yvon van
authors.initials: Yv
authors.lastname: Delft
authors.forename: Christiane
authors.initials: C
authors.lastname: Moecklinghoff
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage*; D018791:CD4 Lymphocyte Count; D000069454:Darunavir; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage*; D015497:HIV-1 / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D019438:Ritonavir / Q000008:administration & dosage*; D013449:Sulfonamides / Q000008:administration & dosage*; D013997:Time Factors; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D013449:Sulfonamides; D019438:Ritonavir; D000069454:Darunavir